Gastroenterology

Acute Pancreatitis

49

Pipeline Programs↗

18

Active Trials↗

19

Companies Involved↗

Acute Pancreatitis is a moderately active landscape with 49 programs across 19 companies. The most active players are Boehringer Ingelheim, Javelin Pharmaceuticals, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. 13 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

19/100

Mech. Concentration

31/100

Completion Rate

75/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Boehringer Ingelheim

2 programs

Javelin Pharmaceuticals

1 program

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

1 program

Ferring

1 program

Validus Pharmaceuticals

1 program

Daewoong Pharmaceutical Co. LTD.

1 program

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

62 of 66 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 66 classified programs, each share of the total. Modality classified for 97% of 70 pipeline programs.

Analysis

Trial Status

65

clinical trials

Completed21 · 32%

Unknown status19 · 29%

Recruiting12 · 18%

Terminated5 · 8%

Not yet recruiting4 · 6%

Active, not recruiting2 · 3%

Other2 · 3%

Clinical Trials

Trial Activity

65 trials

Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.

Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT06253117·60 enrolled

Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency

Recruiting·OOhio State University·Phase 4·NCT06477159·60 enrolled

The Effect of Aspirin on Recurrent Acute Pancreatitis

Recruiting·—·N/A·NCT06185621·23 enrolled

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis

Recruiting·PPanafina, Inc.·Phase 2·NCT06080789·36 enrolled

Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)

Recruiting·PPeking Union Medical College Hospital·Phase 4·NCT03547232·1,504 enrolled

Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis

Recruiting·—·Phase 3·NCT04924868·332 enrolled

Dextran 40 Plus Ringer's Lactate Vs. Ringer's Lactate Alone for Fluid Resuscitation in Acute Pancreatitis

Recruiting·SSatu Mare County Emergency Hospital·N/A·NCT06835023·100 enrolled

Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children

Recruiting·MMedical University of Warsaw·Phase 4·NCT07024199·78 enrolled

Safety and Tolerability of Pirfenidone in Acute Pancreatitis

Recruiting·UUniversity of Alabama at Birmingham·Phase 1/2·NCT05350371·60 enrolled

DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis

Recruiting·UUniversity of Minnesota·N/A·NCT06899087·45 enrolled

Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections

Recruiting·OOrlando Health, Inc.·N/A·NCT06179459·110 enrolled

Phase IIb, Randomised, Double-blind, Placebo-controlled, Multi-centre Trial of Infliximab With Transcriptomic Biomarker and Mechanism Evaluation in Patients With Acute Pancreatitis.

Recruiting·UUniversity of Liverpool·Phase 2·NCT03684278·240 enrolled

High-dose Intravenous Vitamin C for the Treatment of Severe Acute Pancreatitis

Active, not recruiting·RRuijin Hospital·N/A·NCT06897384·388 enrolled

Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis

Active, not recruiting·—·Phase 2/3·NCT04966559·74 enrolled

Endoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis

Not yet recruiting·—·N/A·NCT07093996·200 enrolled

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)